MBX (MBX) CEO Steven Hoerter Receives Stock Awards (RSUs & Options)

What Happened

• Steven L. Hoerter, President, CEO and Director of MBX Biosciences (MBX), received equity awards on 2026-08-03: 71,000 restricted stock units (RSUs) and 331,000 derivative awards (option-style), each reported at $0.00 on the Form 4. These are grants (not open-market purchases or sales) and no cash was reported as paid.

Key Details

• Transaction date: 2026-08-03; Form 4 filed 2026-08-04 (timely).
• Awards reported: 71,000 RSUs (grant) and 331,000 derivative awards (grant); both at $0.00 reported acquisition price.
• Vesting (per footnotes): RSUs vest 25% annually on July 13 of 2027, 2028, 2029 and 2030. The derivative/option awards vest 25% on July 13, 2027, then the remainder in 36 equal monthly installments, all subject to continued service.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Ownership note: Some shares are held by the Steven L. Hoerter Revocable Trust (dated Nov 2, 2018); Hoerter disclaims beneficial ownership of trust shares except to the extent of any pecuniary interest.
• Exhibit included: Power of Attorney (Exhibit 24).

Context

• These were compensation grants (awards), which are routine for executives and designed to retain and incentivize over time; they are not immediate sales or open-market purchases.
• The 331,000 award is reported as a derivative (option-like) award — it vests over time rather than delivering shares immediately.
• Filing was timely (filed one day after the report date); no late-filing flag was indicated.